These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 14695209

  • 1. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
    Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM.
    Cancer Res; 2003 Dec 15; 63(24):8922-9. PubMed ID: 14695209
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 15; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 3. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 15; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 5. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
    Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL.
    Clin Cancer Res; 1999 Jan 15; 5(1):35-42. PubMed ID: 9918200
    [Abstract] [Full Text] [Related]

  • 6. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
    deSolms SJ, Ciccarone TM, MacTough SC, Shaw AW, Buser CA, Ellis-Hutchings M, Fernandes C, Hamilton KA, Huber HE, Kohl NE, Lobell RB, Robinson RG, Tsou NN, Walsh ES, Graham SL, Beese LS, Taylor JS.
    J Med Chem; 2003 Jul 03; 46(14):2973-84. PubMed ID: 12825937
    [Abstract] [Full Text] [Related]

  • 7. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 8. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
    Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer A.
    Cancer Res; 1998 Mar 15; 58(6):1253-9. PubMed ID: 9515813
    [Abstract] [Full Text] [Related]

  • 9. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 15; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 10. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME, Gopal-Truter S, Seeburger G, Bhimnathwala H, Abrams MT, Davide JP, Ellis MS, Gibbs JB, Greenberg I, Koblan KS, Kral AM, Liu D, Lobell RB, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Senderak ET, Oliff A, Kohl NE.
    Cancer Res; 2000 May 15; 60(10):2680-8. PubMed ID: 10825141
    [Abstract] [Full Text] [Related]

  • 11. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K.
    Gan To Kagaku Ryoho; 1997 Sep 15; 24(11):1495-502. PubMed ID: 9309147
    [Abstract] [Full Text] [Related]

  • 12. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 13. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
    Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM.
    Cancer Res; 1999 Oct 01; 59(19):4919-26. PubMed ID: 10519405
    [Abstract] [Full Text] [Related]

  • 14. v-Src transformation is mediated through farnesylated proteins.
    Teng S, Sun J, Irby R, Hamilton AD, Sebti S, Yeatman TJ.
    J Surg Res; 2001 Aug 01; 99(2):343-6. PubMed ID: 11469908
    [Abstract] [Full Text] [Related]

  • 15. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM, Yan N, Cox AD, Bustelo X, Graham SM, Lynch MJ, Weinmann R, Seizinger BR, Der CJ, Barbacid M.
    Oncogene; 1995 May 18; 10(10):1905-13. PubMed ID: 7761092
    [Abstract] [Full Text] [Related]

  • 16. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis.
    Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ.
    Oncogene; 2004 Jan 22; 23(3):706-15. PubMed ID: 14737105
    [Abstract] [Full Text] [Related]

  • 17. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
    Zhang B, Prendergast GC, Fenton RG.
    Cancer Res; 2002 Jan 15; 62(2):450-8. PubMed ID: 11809695
    [Abstract] [Full Text] [Related]

  • 18. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
    Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A, Kohl NE.
    Mol Cell Biol; 1998 Jan 15; 18(1):85-92. PubMed ID: 9418856
    [Abstract] [Full Text] [Related]

  • 19. Involvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells.
    Hamada M, Miki T, Iwai S, Shimizu H, Yura Y.
    Cancer Chemother Pharmacol; 2011 Sep 15; 68(3):559-69. PubMed ID: 21107573
    [Abstract] [Full Text] [Related]

  • 20. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC, Qian Y, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Nov 10; 270(45):26770-3. PubMed ID: 7592913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.